Tempus AI (NASDAQ:TEM) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Tempus AI (NASDAQ:TEM) had its price objective raised by equities researchers at Robert W. Baird from $85.00 to $92.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird‘s target price indicates a potential upside of 17.23% from the company’s current price.

Several other brokerages also recently issued reports on TEM. Piper Sandler raised shares of Tempus AI from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $56.00 to $76.00 in a research note on Tuesday, September 1st. Raymond James Financial set a $80.00 target price on shares of Tempus AI in a research note on Wednesday, September 2nd. Rothschild & Co Redburn assumed coverage on Tempus AI in a report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price target for the company. Roth Capital began coverage on Tempus AI in a research note on Tuesday, September 8th. They set a “neutral” rating and a $67.00 price target on the stock. Finally, Guggenheim increased their price target on Tempus AI from $65.00 to $92.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Eleven equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Tempus AI presently has a consensus rating of “Hold” and an average target price of $79.37.

Tempus AI Stock Performance

NASDAQ:TEM opened at $78.48 on Tuesday. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The company has a market capitalization of $14.16 billion, a P/E ratio of -54.50 and a beta of 3.54. The firm has a 50-day moving average price of $70.80 and a two-hundred day moving average price of $57.12. Tempus AI has a twelve month low of $40.77 and a twelve month high of $90.53.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Monday, November 2nd. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. The company had revenue of $411.54 million during the quarter, compared to analysts’ expectations of $409.39 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%. The business’s revenue for the quarter was up 23.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.46) earnings per share. As a group, research analysts expect that Tempus AI will post -1.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Ryan Fukushima sold 41,095 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $2,038,722.95. Following the sale, the chief executive officer directly owned 562,463 shares of the company’s stock, valued at $27,903,789.43. This represents a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 22,148 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the transaction, the executive vice president owned 146,067 shares in the company, valued at $7,246,383.87. This trade represents a 13.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 1,256,777 shares of company stock worth $86,356,352. 24.26% of the stock is owned by insiders.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors have recently modified their holdings of TEM. Eagle Health Investments LP bought a new stake in Tempus AI in the first quarter worth approximately $11,588,000. Aristotle Atlantic Partners LLC bought a new position in shares of Tempus AI during the 1st quarter valued at $6,179,000. Headlands Technologies LLC bought a new position in shares of Tempus AI during the 2nd quarter valued at $2,689,000. Odyssean LLC bought a new position in shares of Tempus AI during the 2nd quarter valued at $897,000. Finally, Canal Insurance CO lifted its stake in shares of Tempus AI by 100.0% in the 1st quarter. Canal Insurance CO now owns 40,000 shares of the company’s stock valued at $1,809,000 after purchasing an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations. Tempus reported adjusted earnings of $0.07 per share versus the expected $0.09 loss, while revenue rose 23.1% year over year to $411.54 million, slightly above the $409.39 million consensus. The narrower loss and strong top-line growth were the primary catalysts for the stock’s advance. Tempus Reports Third Quarter 2026 Results
• Positive Sentiment: Management raised its 2026 revenue outlook. Tempus now expects approximately $1.60 billion to $1.605 billion in 2026 revenue and continues to target about $65 million in adjusted EBITDA. Investors were encouraged by growth in the Data and Applications segment, which expanded 33% and carries gross margins above 71%, as well as the company’s collaboration with Bristol Myers Squibb. Tempus 2026 Revenue Outlook
• Positive Sentiment: Analyst and trading signals improved. Needham raised its price target from $75 to $89 and maintained a Buy rating. Trading activity also showed elevated call-option demand, while Cathie Wood’s Ark Investment Management reportedly purchased about $11.2 million of TEM shares, adding to bullish sentiment.
• Neutral Sentiment: Analyst views remain mixed. UBS reiterated a Hold rating with an $80 price target, citing solid oncology execution but weaker hereditary testing. This suggests the earnings beat was encouraging, but some analysts remain cautious about the pace and quality of growth. Tempus UBS Rating
• Negative Sentiment: Personalis acquisition risks remain. Reports highlight potential challenges integrating Personalis, including execution complexity and the possibility that deal-related costs or operational disruption could weigh on future performance. Personalis Integration Risks

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.